HANSOH PHARMA Shares Surge on Positive Phase III Trial Results for Lung Cancer Drug

Stock News07-13

Shares of HANSOH PHARMA (03692) rose more than 3% in trading today.

At the time of writing, the stock was up 3.38% to HK$32.94, with a trading volume of HK$127 million.

The increase follows an announcement from the company regarding its drug candidate HS-20093.

The group announced that its self-developed B7-H3-targeting antibody-drug conjugate, HS-20093, has met the primary endpoint of overall survival in a pivotal Phase III clinical trial.

The trial, named ARTEMIS-008, evaluated the drug in patients with small cell lung cancer who had progressed or relapsed after platinum-based therapy.

At a pre-specified interim analysis, HS-20093 demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to the chemotherapy agent topotecan.

Consistent benefits were also observed in key secondary endpoints, including progression-free survival.

The drug's safety profile was consistent with previous study findings, with no new safety signals identified.

Based on these positive outcomes, the group plans to initiate discussions with regulatory authorities shortly to prepare for a new drug application submission in China.

Detailed results from the ARTEMIS-008 study are expected to be presented at an upcoming international oncology conference.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115132034?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115132034","market":"sg","top_or_hot":-1,"title":"HANSOH PHARMA Shares Surge on Positive Phase III Trial Results for Lung Cancer Drug","media":"Stock News","content":"<p>Shares of <b>HANSOH PHARMA</b> (<b>03692</b>) rose more than 3% in trading today.<br><br>At the time of writing, the stock was up 3.38% to HK$32.94, with a trading volume of HK$127 million.<br><br>The increase follows an announcement from the company regarding its drug candidate HS-20093.<br><br>The group announced that its self-developed B7-H3-targeting antibody-drug conjugate, HS-20093, has met the primary endpoint of overall survival in a pivotal Phase III clinical trial.<br><br>The trial, named ARTEMIS-008, evaluated the drug in patients with small cell lung cancer who had progressed or relapsed after platinum-based therapy.<br><br>At a pre-specified interim analysis, HS-20093 demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to the chemotherapy agent topotecan.<br><br>Consistent benefits were also observed in key secondary endpoints, including progression-free survival.<br><br>The drug's safety profile was consistent with previous study findings, with no new safety signals identified.<br><br>Based on these positive outcomes, the group plans to initiate discussions with regulatory authorities shortly to prepare for a new drug application submission in China.<br><br>Detailed results from the ARTEMIS-008 study are expected to be presented at an upcoming international oncology conference.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA Shares Surge on Positive Phase III Trial Results for Lung Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA Shares Surge on Positive Phase III Trial Results for Lung Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-13 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>HANSOH PHARMA</b> (<b>03692</b>) rose more than 3% in trading today.<br><br>At the time of writing, the stock was up 3.38% to HK$32.94, with a trading volume of HK$127 million.<br><br>The increase follows an announcement from the company regarding its drug candidate HS-20093.<br><br>The group announced that its self-developed B7-H3-targeting antibody-drug conjugate, HS-20093, has met the primary endpoint of overall survival in a pivotal Phase III clinical trial.<br><br>The trial, named ARTEMIS-008, evaluated the drug in patients with small cell lung cancer who had progressed or relapsed after platinum-based therapy.<br><br>At a pre-specified interim analysis, HS-20093 demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to the chemotherapy agent topotecan.<br><br>Consistent benefits were also observed in key secondary endpoints, including progression-free survival.<br><br>The drug's safety profile was consistent with previous study findings, with no new safety signals identified.<br><br>Based on these positive outcomes, the group plans to initiate discussions with regulatory authorities shortly to prepare for a new drug application submission in China.<br><br>Detailed results from the ARTEMIS-008 study are expected to be presented at an upcoming international oncology conference.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"","article_id":"1115132034","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115132034","pubTimestamp":1783908161,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of HANSOH PHARMA (03692) rose more than 3% in trading today.At the time of writing, the stock was up 3.38% to HK$32.94, with a trading volume of HK$127 million.The increase follows an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4134":"信息科技咨询与其它服务","KCAI":"KraneShares China Alpha Index ETF","VXUS":"国际股票ETF-Vanguard","BK1583":"高瓴概念","BK1589":"北水核心资产","BK1191":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","03692":"翰森制药","III":"信息服务"},"translate_title":"豪森制药肺癌药物三期试验结果积极，股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1,"KCAI":1,"III":1,"VXUS":1},"content_text":"Shares of HANSOH PHARMA (03692) rose more than 3% in trading today.At the time of writing, the stock was up 3.38% to HK$32.94, with a trading volume of HK$127 million.The increase follows an announcement from the company regarding its drug candidate HS-20093.The group announced that its self-developed B7-H3-targeting antibody-drug conjugate, HS-20093, has met the primary endpoint of overall survival in a pivotal Phase III clinical trial.The trial, named ARTEMIS-008, evaluated the drug in patients with small cell lung cancer who had progressed or relapsed after platinum-based therapy.At a pre-specified interim analysis, HS-20093 demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to the chemotherapy agent topotecan.Consistent benefits were also observed in key secondary endpoints, including progression-free survival.The drug's safety profile was consistent with previous study findings, with no new safety signals identified.Based on these positive outcomes, the group plans to initiate discussions with regulatory authorities shortly to prepare for a new drug application submission in China.Detailed results from the ARTEMIS-008 study are expected to be presented at an upcoming international oncology conference.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115132034","isCrawlerRequest":true}